RxDoctor Payments Data

Hector Maldonado

Neurology · El Paso, TXNPI 1457369050

Payments from drug & device makers

$30,589in general payments, 2019–2025

Across 120 payments — averaging $254.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$27K
  • EMD Serono, Inc.$1K
  • AstraZeneca$437
  • Sanofi$396
  • Amgen$331
  • Teva Pharmaceuticals USA, Inc.$182
  • plus $801 from 8 others

What the payments were for

  • Consulting fees$9,44831%
  • Speaking & faculty fees$15,63051%
  • Travel & lodging$7642%
  • Food & beverage$4,34014%
  • Education$4071%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,589 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$65,286
Medicare patients
286
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$277,417
VumerityDiroximel Fumarate26$234,004
RebifInterferon Beta-1a/Albumin12$133,068
ZeposiaOzanimod Hydrochloride14$127,694
AubagioTeriflunomide11$102,476
XcopriCenobamate69$95,110
AmpyraDalfampridine17$72,972
GlatopaGlatiramer Acetate15$65,083
NourianzIstradefylline18$60,053
Aimovig AutoinjectorErenumab-Aooe23$54,985
Glatiramer Acetate24$48,021
Teriflunomide31$42,576
NeuproRotigotine21$35,479
Carbamazepine ErCarbamazepine106$23,681
Emgality PenGalcanezumab-Gnlm12$23,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$27,381$234,00426 claims
EMD Serono, Inc.Rebif$1,062$133,06812 claims
SanofiAubagio$396$102,47611 claims
SK Life Science, Inc.Xcopri$125$95,11069 claims
UCB, Inc.Neupro, Briviact$125$52,42933 claims
AbbVieNamzaric$34$21,92115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →